-
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update
05 Aug 2025 10:00 GMT
… 2025.
Esperion’s European partner Daiichi Sankyo Europe (DSE) continues to show …
-
Late-Stage Pipeline Wins Boost Investor Confidence In High-Growth Therapeutic Areas - Financial News Media
04 Aug 2025 18:53 GMT
… jointly developed by Merck and Daiichi Sankyo. While localized prostate cancer has …
-
Neuroendocrine Prostate Cancer Market Forecast Shows Accelerated CAGR Due to Diagnostic Advancements and Research Investment | DelveInsight
04 Aug 2025 17:00 GMT
… Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra … Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra … Holdings, Kintor Pharmaceutical, MacroGenics, Daiichi Sankyo, Madison Vaccines, Novartis, Point …
-
Assay may aid antibody-drug conjugate therapy selection for breast cancer
04 Aug 2025 14:43 GMT
… -nxki (T-DXd; Enhertu; AstraZeneca, Daiichi Sankyo) plus pertuzumab (Perjeta, Genentech) reduced … and datopotamab deruxtecan (AstraZeneca/Daiichi Sankyo) in individuals with metastatic HER2 …
-
1 Blue-Chip Dividend Stock That Still Has Room to Run
02 Aug 2025 06:24 GMT
… era. Through a collaboration with Daiichi Sankyo, Merck is advancing ifinatamab deruxtecan …
-
Making New Connections: Antibody Drug Conjugates Target Cancer
01 Aug 2025 17:01 GMT
… therapeutic developed by AstraZeneca and Daiichi Sankyo. Enhertu chemically links trastuzumab, a …
-
As Enhertu expands, AstraZeneca taps Korean startup AIVIS for AI-powered HER2 reads
01 Aug 2025 07:35 GMT
… conjugate AstraZeneca co-developed with Daiichi Sankyo.
“Reading HER2-ultralow slides isn …
-
Enhertu and Trodelvy Show Promise for First-Line Metastatic Breast Cancer Treatment
01 Aug 2025 02:01 GMT
… effects. Enhertu, from AstraZeneca and Daiichi Sankyo, and Trodelvy, from Gilead Sciences … eligible for Keytruda. AstraZeneca/Daiichi Sankyo and Gilead intend to submit …
-
Chronic Pain Associated with Painful Diabetic Neuropathy Market Sees is Predicted to Surge During the Forecast Period (2025–2034) with New Treatment Innovations and Expanding Research Spending | DelveInsight
31 Jul 2025 17:00 GMT
… ) Biotech Pty Ltd., WinSanTor, Inc., Daiichi Sankyo, Inc., Avazzia, Inc., among others …
-
Emrelis Could Establish AbbVie as a Competitor in MET-High NSCLC Treatment
29 Jul 2025 20:23 GMT
… increasing competition from companies like Daiichi Sankyo, Seagen, and ImmunoGen?
Neha Anand … it apart from competitors like Daiichi Sankyo, Seagen, and ImmunoGen, which are … rising competition from companies like Daiichi Sankyo and ImmunoGen.